Key facts
- Scithera’s last known valuation is $60.0M (May 2025).
- It has raised $26.0M; the latest was Early Stage VC ($26.0M) in May 2025.
- Notable investors include Venrock.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Scithera
- ·The full record, as it builds
Funding rounds
No funding rounds for Scithera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Scithera
Developer of noval antibody design for drug conjugates.based in California . The company is currently operating in stealth mode.
- Sector
- Business Products and Services (B2B)
- HQ
- SAN DIEGO, CA, United States
- Founded
- 2025
- Website
- scithera.bio/
- Ownership
- Privately Held (backing)
Scithera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Scithera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Scithera in its N-PORT filings yet. We sweep new filings monthly.